» Articles » PMID: 15198549

Aerodynamic Particle Size Analysis of Aerosols from Pressurized Metered-dose Inhalers: Comparison of Andersen 8-stage Cascade Impactor, Next Generation Pharmaceutical Impactor, and Model 3321 Aerodynamic Particle Sizer Aerosol Spectrometer

Overview
Publisher Springer
Specialty Pharmacology
Date 2004 Jun 17
PMID 15198549
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this research was to compare three different methods for the aerodynamic assessment of (1) chloroflurocarbon (CFC)--fluticasone propionate (Flovent), (2) CFC-sodium cromoglycate (Intal), and (3) hydrofluoroalkane (HFA)--beclomethasone dipropionate (Qvar) delivered by pressurized metered dose inhaler. Particle size distributions were compared determining mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction <4.7 microm aerodynamic diameter (FPF(<4.7 microm)). Next Generation Pharmaceutical Impactor (NGI)-size distributions for Flovent comprised finer particles than determined by Andersen 8-stage impactor (ACI) (MMAD = 2.0 +/- 0.05 micro m [NGI]; 2.8 +/- 0.07 microm [ACI]); however, FPF(<4.7 microm) by both impactors was in the narrow range 88% to 93%. Size distribution agreement for Intal was better (MMAD = 4.3 +/- 0.19 microm (NGI), 4.2 +/- 0.13 microm (ACI), with FPF(<4.7 microm) ranging from 52% to 60%. The Aerodynamic Particle Sizer (APS) undersized aerosols produced with either formulation (MMAD = 1.8 +/- 0.07 micro m and 3.2 +/- 0.02 micro m for Flovent and Intal, respectively), but values of FPF(<4.7 microm)from the single-stage impactor (SSI) located at the inlet to the APS (82.9% +/- 2.1% [Flovent], 46.4% +/- 2.4% [Intal]) were fairly close to corresponding data from the multi-stage impactors. APS-measured size distributions for Qvar (MMAD = 1.0 +/- 0.03 micro m; FPF(<4.7 micro m)= 96.4% +/- 2.5%), were in fair agreement with both NGI (MMAD = 0.9 +/- 0.03 micro m; FPF(<4.7 microm)= 96.7% +/- 0.7%), and ACI (MMAD = 1.2 +/- 0.02 microm, FPF(<4.7 microm)= 98% +/- 0.5%), but FPF(<4.7 microm) from the SSI (67.1% +/- 4.1%) was lower than expected, based on equivalent data obtained by the other techniques. Particle bounce, incomplete evaporation of volatile constituents and the presence of surfactant particles are factors that may be responsible for discrepancies between the techniques.

Citing Articles

Engineering of inhalable nano-in-microparticles for co-delivery of small molecules and miRNAs.

Motiei M, Misik O, Truong T, Lizal F, Humpolicek P, Sedlarik V Discov Nano. 2023; 18(1):38.

PMID: 37382704 PMC: 10214903. DOI: 10.1186/s11671-023-03781-0.


Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.

Gao J, Xia Z, Vohidova D, Joseph J, Luo J, Joshi N Acta Pharm Sin B. 2023; 13(4):1400-1428.

PMID: 37139423 PMC: 10150162. DOI: 10.1016/j.apsb.2022.07.010.


Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms.

Jiang J, Ma X, Ouyang D, Williams 3rd R Pharmaceutics. 2022; 14(11).

PMID: 36365076 PMC: 9694557. DOI: 10.3390/pharmaceutics14112257.


Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice.

Gan C, Luo W, Yu Y, Jiao Z, Li S, Su D NPJ Vaccines. 2021; 6(1):87.

PMID: 34158496 PMC: 8219734. DOI: 10.1038/s41541-021-00349-w.


Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned.

Bianco F, Salomone F, Milesi I, Murgia X, Bonelli S, Pasini E Respir Res. 2021; 22(1):71.

PMID: 33637075 PMC: 7908012. DOI: 10.1186/s12931-020-01585-9.


References
1.
Mitchell J, Nagel M, Archer A . Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API Aerosizer time-of-flight aerodynamic particle size analyzer. J Aerosol Med. 2000; 12(4):255-64. DOI: 10.1089/jam.1999.12.255. View

2.
Cripps A, Riebe M, Schulze M, Woodhouse R . Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000; 94 Suppl B:S3-9. View

3.
Chew N, Bagster D, Chan H . Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm. 2000; 206(1-2):75-83. DOI: 10.1016/s0378-5173(00)00516-0. View

4.
Nagel M, Wiersema K, Bates S, Mitchell J . Size analysis of a pressurized metered dose inhaler-delivered solution formulation by an Aerosizer-LD time-of-flight aerosol particle size spectrometer. J Aerosol Med. 2002; 15(1):75-85. DOI: 10.1089/08942680252908601. View

5.
Mitchell J, Nagel M . Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols. J Aerosol Med. 2000; 12(4):217-40. DOI: 10.1089/jam.1999.12.217. View